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The panoply of treatment algorithms, periodically released to improve guidance, is one mean to face therapeutic
uncertainty in pharmacological management of hyperglycemia in type 2 diabetes, especially after metformin failure.
Failure of recent guidelines to give advice on the use of specific antidiabetic drugs in patients with co-morbidity
may generate further uncertainty, given the frequent association of type 2 diabetes with common comorbidity,
including, although not limited to obesity, cardiovascular disease, impaired renal function, and frailty. The Italian
Association of Diabetologists (Associazione Medici Diabetologi, AMD) recognized the need to develop personalized
treatment plans for people with type 2 diabetes, taking into account the patients' individual profile (phenotype),
with the objective of the safest possible glycemic control. As not every subject with type 2 diabetes benefits from
intensive glycemic control, flexible regimens of treatment with diabetes drugs (including insulin) are needed for
reaching individualized glycemic goals. Whether personalized diabetology will improve the quality healthcare
practice of diabetes management is unknown, but specific research has been launched.Introduction
In 2011, there were 366 million people with diabetes
worldwide, and this is expected to rise to 552 million by
2030, rendering previous estimates very conservative [1].
Diabetes increases the risk of disabling and life-threatening
complications from micro and macrovascular disease.
Diabetes is one of the first conditions for which disease-
specific indicators based on practice guidelines have been
used to “score” the quality of care and preventive services.
Recent estimates in the US claim that about one half
(48.7%) of persons with diabetes still did not meet the tar-
gets for glycemic control; only 14.3% met the targets for
all three measures of glycemic control (HbA1c <7%),
blood pressure (<130/80 mm Hg), or LDL cholesterol
(<100 mg/dl) level [2]. This scenario is still far from the
objectives of glycemic therapies in type 2 diabetes which,
in addition to achieving target HbA1c, ideally should: a)
reverse one or more of the underlying pathophysiological
processes, b) produce low unwanted effects, c) enhance
quality of life of patients, and d) reduce diabetes micro* Correspondence: katherine.esposito@unina2.it
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reproduction in any medium, provided the orand macrovascular complications, and diabetes-related
mortality [3].Clinical uncertainty
Uncertainties abound in healthcare. Although clinical
uncertainty was supposed to present only rarely manage-
ment problems for the doctor, it appeared soon as one
most important single factor influencing physician be-
havior [4]. Clinical uncertainty arising from a number of
sources has been managed, at least in part, through
evidence-based medicine that helps clinicians convert the
data of scientific studies into probabilities that can help re-
duce uncertainty. However, one of the major hurdles is
faced by clinicians on daily basis is selecting the best avail-
able evidence. Still today, some questions cannot be an-
swered, no matter how one searches the literature, no
matter which expert one consult [5]. Unavoidable clinical
uncertainty may have the potential to contribute to clinical
inertia, defined as the failure of health care providers to
initiate or intensify therapy when indicated [6]. Uncer-
tainty about effectiveness is the oldest source of clinical
uncertainty, and is not limited to diabetes: it pushes physi-
cians to rely on inductive reasoning to draw conclusions
about the effectiveness and feasibility of application of triall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Management of hyperglycemia in type 2 diabetes
Uncertainties also abound in pharmacological manage-
ment of hyperglycemia in type 2 diabetes. Sources of un-
certainties include, but are not limited to, the panoply of
glycemic (HbA1c) targets, the ideal sequence of drugs
after metformin failure, the complexity of drug therapy,
the possible harms of anti-hyperglycemic drugs, the out-
comes of treatment (surrogate versus clinical), and the
hierarchy of risk factors to treat in order to prevent the
vascular complications. The rising number of diabetes
medications available today (more tomorrow) makes it
hard, if not impossible, to explore all possible combina-
tions and sequences of combinations that could be
recommended. As a corollary, treatment algorithms can-
not be truly evidence-based because of a lack of studies
comparing all available treatment combination options.
Another source of uncertainty was recently addressed
by Tschöpe et al. [7], who stressed the failure of recent
guidelines to give advice on the use of specific antidiabeticFigure 1 Therapeutic algorithm developed by the Italian Association
diabetes phenotypes.Starting page. The algorithm can be found at httpdrugs in patients with co-morbidity. As the patient with
type 2 diabetes represents the paradigm of associated co-
morbidities (overweight or obesity, dyslipidemia, hyper-
tension, cardiovascular disease, impaired renal function),
the expert opinion released by Tschöpe and colleagues [7]
seems well-timed from a clinical practice perspective. The
evidence presented in support of their expert opinion was
the best available; however, the divarication between the
world of randomized controlled trials (RCTs) and the real
world of the average type 2 diabetic patient remains prob-
lematic. The otherwise very complete Figure accompany-
ing the article is a long list of drugs recommended,
contraindicated or neutral, among which clinicians may
pick up the most appropriate drug for that particular pa-
tient, based on their own clinical judgment (a mixture of
clinical experience, knowledge and skill).
Recently, the Italian Association of Diabetologists
(Associazione Medici Diabetologi, AMD) recognized the
need to develop personalized treatment plans for people
with type 2 diabetes, taking into account the patient s
individual profile (phenotype), with the objective of the saf-
est possible glycometabolic control. Accordingly, tailoredof Diabetologists (AMD) for some of the most common type 2
://www.aemmedi.it/algoritmi_it_2013. Accessed 1 June 2013.
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the most common type 2 diabetes phenotypes [8], as
reported, for example, in Figure 1. These algorithms are
available in English online as a browser operated inter-
active version [9]. The reader can quickly locate the sub-
ject of interest according to his or her clinical features,
and also easily follow a step-by-step suggested additive
therapeutic pathway. Online publication facilitates timely
updating of the recommendations, ensuring that all
healthcare professionals have the latest version of the algo-
rithms readily available at their office. Hopefully, this
would also allow for a better adherence to drug therapy. A
retrospective analysis of pharmacy claims in a database of
more than 64 million members enrolled in 100 health
plans assessed persistence and adherence to drug therapy
in 6 chronic conditions including type 2 diabetes: 12-
month adherence rate for oral antidiabetic drugs was 72%,
and as low as 40% at 2 year [10].
Set the HbA1c target, first
The choice of the HbA1c target was a neglected area in
the expert opinion [7]. This is not without practical con-
sequence, as the preliminary individualization of the
appropriate HbA1c target for the particular patient
physician faces in the real word can remove some of the
inconsistencies and gaps with respect to the selection of
antidiabetic drug treatment in patients with co-morbid
disease conditions. Take, for example, the presence of
macrovascular complications in a middle-aged (arbitrar-
ily defined as >45 years) or elderly (>70 years) patient: in
these situations, the target would necessarily be trans-
lated to upper levels (from 7 to 8% HbA1c), which
would result in a lesser aggressive therapeutic pattern,
and hence lower side-effects (drug-related). The premise
that not every subject with type 2 diabetes benefits from
intensive glycemic control, consequently leads setting up
flexible regimens of treatment with diabetes drugs
(including insulin) and providing individualized glycemic
goals and ongoing professional support [11].
Obesity
Obesity is a frequent co-morbidity of type 2 diabetes. The
World Health Organization estimates that obesity ac-
counts for 44% of the global diabetes burden, 23% of the
ischemic heart disease burden and 7–41% of the burden
of certain cancers globally [12]. Even modest weight loss
(5–10% of body weight) has been shown to improve meta-
bolic function and reduce the risk of comorbidities in
obese individuals [13]. As a corollary, diabetes drugs that
are associated with an unwanted effect of weight gain
should be avoided or used wisely. For obese, metformin-
treated patients who fail to achieve the individualized tar-
get for HbA1c, second-line treatment choices in order
of weight benefit would be: GLP-1 agonists, DPP-4inhibitors, acarbose, bile acid sequestrants, and amylin
analogs [7]. In a meta-analysis of GLP-1-based therap-
ies, GLP-1 agonists were associated with significant
body-weight reductions from baseline ranging from 2 to
2.4 kg [14]. The incretin effect of GLP-1 is impaired in
obesity, and this may contribute to the hyperglycemia,
increased appetite and faster gastric emptying that often
accompany obesity. In the AMD portfolio, GLP1-agonists
are suggested as the first choice for those obese diabetic
patients failing metformin, with the only exception of
those with isolated postprandial hyperglycemia, where
acarbose may also be considered.
Is personalized diabetology the answer?
Usually accompanying pharmacogenetics, genomics and
cancer medicine, personalized medicine is a medical
model emphasizing the customization of healthcare,
with all decisions and practices being tailored to individ-
ual patients in whatever ways possible. Development
strategies that administer therapies to unselected po-
pulations will perhaps become a strategy of the past.
However, physician feeling and conviction about the
willingness to reach the HbA1c target (now tailored on
the patient) remains paramount to reduce unnecessary
therapeutic inertia. Suggested choices within the algo-
rithm represent the best compromise among the scien-
tific evidence of efficacy and safety coming from RCTs,
and the translation in the real word of type 2 diabetes.
For the pragmatic physician, however, the evidence
that intensive glycemic control may give benefit on
microvascular complications of type 2 diabetes [15] may
be just enough to accept and propose it for most dia-
betic patients. This, however, must be tempered with the
evidence that intensive glycemic control increases the
risk of severe hypoglycemia [16,17]. Fourteen clinical tri-
als that randomized 28 614 participants with type 2
diabetes (15 269 to intensive control and 13 345 to con-
ventional control) were included in a meta-analysis that
considered the effects of intensive glycemic control irre-
spective of differences among trials in individual targets
or achieved glycemic control [17].
Personalized diabetology [18] has the potential to im-
prove the quality healthcare practice of diabetes ma-
nagement, but specific research is needed. Personalized
diabetology should also take advantage from techno-
logical advances and interventions involving mobile ap-
plications that may have a positive impact on diabetes
self-management [19]. A recent controlled study suggests
that a nurse-led online disease management program can
achieve greater decreases in A1C at 6 months, although
the differences were not sustained at 12 months [20]. It
is not by chance that AMD has launched an interven-
tional, national-planned, trial specifically devoted to test
the hypothesis whether a strict adherence to the
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comes for type 2 diabetic patients.
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